CY1109316T1 - Συνδυαστικη αγωγη για πολλαπλη σκληρυνση - Google Patents

Συνδυαστικη αγωγη για πολλαπλη σκληρυνση

Info

Publication number
CY1109316T1
CY1109316T1 CY20091100869T CY091100869T CY1109316T1 CY 1109316 T1 CY1109316 T1 CY 1109316T1 CY 20091100869 T CY20091100869 T CY 20091100869T CY 091100869 T CY091100869 T CY 091100869T CY 1109316 T1 CY1109316 T1 CY 1109316T1
Authority
CY
Cyprus
Prior art keywords
cda
alpha
agent
integrin antibody
combination
Prior art date
Application number
CY20091100869T
Other languages
English (en)
Inventor
Luca Giampiero De
Original Assignee
Merck Serono S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Serono S.A. filed Critical Merck Serono S.A.
Publication of CY1109316T1 publication Critical patent/CY1109316T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen

Abstract

Η εφεύρεση εστιάζεται προς αγωγές για πολλαπλή σκλήρυνση οι οποίες περιλαμβάνουν τη χορήγηση σε έναν ασθενή ο οποίος έχει ανάγκη αυτών ενός πρώτου παράγοντα, όπως 2-χλωρο-2'-δεοξυαδενοσίνης, ο οποίος μειώνει τον αριθμό των λευκοκυττάρων σε συνδυασμό με έναν δεύτερο παράγοντα, όπως ένα αντίσωμα αντι-άλφα-4 ιντεγκρίνης, το οποίο παρεμποδίζει την προσκόλληση μονοκυττάρων και λευκοκυττάρων σε ενδοθηλιακά κύτταρα. Η χρήση 2-CdA συνδυασμένης με ένα αντίσωμα αντι-άλφα-4 ιντεγκρίνης μπορεί να είναι πιο αποτελεσματική απ' ότι εκάτερη αγωγή μόνη για MS. Επιπροσθέτως, η συνδυαστική αγωγή μπορεί να καταστήσει δυνατή την ελάττωση ή την μεταβολή της δόσης ενός ή περισσότερων από τους παράγοντες για να περιοριστούν οποιεσδήποτε επιβλαβείς επιδράσεις συνδεόμενες με τους ξεχωριστούς παράγοντες, αλλά διατηρώντας την ίδια θεραπευτική δραστικότητα.
CY20091100869T 2004-12-22 2009-08-12 Συνδυαστικη αγωγη για πολλαπλη σκληρυνση CY1109316T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63867404P 2004-12-22 2004-12-22
EP04106910 2004-12-22
EP05823965A EP1835922B1 (en) 2004-12-22 2005-12-20 Combination treatment for multiple sclerosis

Publications (1)

Publication Number Publication Date
CY1109316T1 true CY1109316T1 (el) 2014-07-02

Family

ID=35789196

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20091100869T CY1109316T1 (el) 2004-12-22 2009-08-12 Συνδυαστικη αγωγη για πολλαπλη σκληρυνση

Country Status (17)

Country Link
US (1) US20100129353A1 (el)
EP (1) EP1835922B1 (el)
JP (1) JP2008524310A (el)
AT (1) ATE431740T1 (el)
AU (1) AU2005318183B2 (el)
CA (1) CA2590471A1 (el)
CY (1) CY1109316T1 (el)
DE (1) DE602005014570D1 (el)
DK (1) DK1835922T3 (el)
ES (1) ES2325552T3 (el)
HR (1) HRP20090417T1 (el)
IL (1) IL183924A (el)
NO (1) NO20073635L (el)
PL (1) PL1835922T3 (el)
PT (1) PT1835922E (el)
SI (1) SI1835922T1 (el)
WO (1) WO2006067134A1 (el)

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2521565B1 (fr) * 1982-02-17 1985-07-05 Dior Sa Parfums Christian Melange pulverulent de constituants lipidiques et de constituants hydrophobes, procede pour le preparer, phases lamellaires lipidiques hydratees et procede de fabrication, compositions pharmaceutiques ou cosmetiques comportant des phases lamellaires lipidiques hydratees
FR2534487B1 (fr) * 1982-10-15 1988-06-10 Dior Christian Parfums Procede d'homogeneisation de dispersions de phases lamellaires lipidiques hydratees, et suspensions obtenues par ce procede
US5310732A (en) * 1986-02-03 1994-05-10 The Scripps Research Institute 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
US5077211A (en) * 1988-07-06 1991-12-31 Applied Genetics, Inc. Purification and administration of dna repair enzymes
GB9206318D0 (en) * 1992-03-24 1992-05-06 Cambridge Antibody Tech Binding substances
US6172197B1 (en) * 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) * 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5871907A (en) * 1991-05-15 1999-02-16 Medical Research Council Methods for producing members of specific binding pairs
US6225447B1 (en) * 1991-05-15 2001-05-01 Cambridge Antibody Technology Ltd. Methods for producing members of specific binding pairs
ES2136092T3 (es) * 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
PT1024191E (pt) * 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5872215A (en) * 1991-12-02 1999-02-16 Medical Research Council Specific binding members, materials and methods
US5208327A (en) * 1991-12-18 1993-05-04 Ortho Pharmaceutical Corporation Intermediates useful in a synthesis of 2-chloro-2'-deoxyadenosine
US5733743A (en) * 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5837242A (en) * 1992-12-04 1998-11-17 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
US5840299A (en) * 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US6001809A (en) * 1994-07-11 1999-12-14 Elan Pharmaceuticals, Inc. Inhibitors of leukocyte adhesion
GB9712818D0 (en) * 1996-07-08 1997-08-20 Cambridge Antibody Tech Labelling and selection of specific binding molecules
US6194395B1 (en) * 1999-02-25 2001-02-27 Orthro-Mcneil Pharmaceutical, Inc. Cyclodextrin cladribine formulations
SI2336184T1 (sl) * 2002-02-25 2015-04-30 Biogen Idec Ma Inc. Dajanje sredstev za zdravljenje vnetij
CN101912615B (zh) * 2003-03-28 2013-03-27 阿莱斯贸易有限公司 用于改善的经口和透粘膜输送的克拉屈滨制剂

Also Published As

Publication number Publication date
JP2008524310A (ja) 2008-07-10
IL183924A (en) 2010-11-30
EP1835922B1 (en) 2009-05-20
ATE431740T1 (de) 2009-06-15
NO20073635L (no) 2007-09-24
AU2005318183B2 (en) 2011-03-31
US20100129353A1 (en) 2010-05-27
PT1835922E (pt) 2009-07-08
HRP20090417T1 (en) 2009-09-30
SI1835922T1 (sl) 2009-10-31
CA2590471A1 (en) 2006-06-29
ES2325552T3 (es) 2009-09-08
DK1835922T3 (da) 2009-08-03
DE602005014570D1 (el) 2009-07-02
EP1835922A1 (en) 2007-09-26
PL1835922T3 (pl) 2009-10-30
IL183924A0 (en) 2007-10-31
AU2005318183A1 (en) 2006-06-29
WO2006067134A1 (en) 2006-06-29

Similar Documents

Publication Publication Date Title
FR2869231B1 (fr) Composition therapeutique contenant au moins un derive de la pyrrolobenzodiazepine et la fludarabine
GB2506085A (en) Combination treatment (eg with ABT-072 or ABT-333) of DAAS for use in treating HCV
BR0308090A (pt) conjugados de agentes citotóxicos ou terapêuticos e peptìdios biologicamente ativos
UA101309C2 (ru) Антагонисты активина-actrii и их применение для повышения уровня эритроцитов
ITMI20041550A1 (it) Uso di batteri probiotici per la preparazione di composizioni topiche per la protezione dell'epidermide
NO332893B1 (no) Anvendelse av antistoff for fremstilling av medikament til anvendelse ved CVP-kjemoterapi
DE60318192D1 (de) Verwendung von a2a adenosin rezeptor agonisten und anti-pathogene mittel enthaltenden kombinationen zur behandlung von entzündungskrankheiten
BRPI0516531A (pt) imunoterapia de distúrbios auto-imunes
CO5700791A2 (es) Metodos para tratar enfermedades relacionadas con interleukin-6
CY1107467T1 (el) Χρηση οξεογονων υδρογονοτροφων στελεχων για την προληψη ή την αγωγη πεπτικων διαταραχων
HUP0002755A2 (hu) Eljárások szklerózis multiplexben szenvedő betegek kezelésére konszenzus interferonnal
NO20052362L (no) Fremgangsmater for administrering av dalbavancin for behandling av bakterielle infeksjoner
ATE423114T1 (de) Aminocyclopropancarbonsäureamidderivate als bradykininantagonisten
NO20064287L (no) Dalbavancin-materialer for behandling av bakterielle infeksjoner
DE60114406D1 (de) Wirkstoffabgabesysteme zur behandlung von gefässerkrankungen
DK1140198T3 (da) Anvendelse af hyaluronan til fremstilling af et lægemiddel til forögelse af cytotoksiske lægemidlers virkningsgrad
HK1112721A1 (en) Tissue disruption treatment and composition for use thereof
PH12021550965A1 (en) Combination therapy for treatment of hematological diseases
CY1113488T1 (el) Ενα φαρμακο για την δυο βαθμιδων περιεγχειρητικη θεραπεια συμπαγων ογκων δια ραδιοανοσοθεραπειας
BR0310061A (pt) Métodos para o tratamento de doenças e condições respiratórias com um inibidor seletivo da inos e um inibidor da pde e suas composições
CY1109316T1 (el) Συνδυαστικη αγωγη για πολλαπλη σκληρυνση
HUP0204208A2 (hu) Pruritus kezelésére szolgáló külsőleges gyógyszerkészítmény
TW200628162A (en) Combination treatment for multiple sclerosis
WO2008060535A3 (en) Use of reversine and analogs for treatment of cancer
TH100271B (th) การบำบัดแบบมีการรวมสำหรับโรคปลอกประสาทเสื่อมแข็ง